Switch theme
Sign up to access all valuation multiples
Jilin Aodong Pharmaceutical Group Co Ltd is engaged in manufacturing of pharmaceuticals. Its products include Anshen Bunao Liquid, Antelope Cough Syrup, Yangxue Yin Oral Liquid, Xinnao Shutong Capsule, Calf Spleen Extract Injection, Xuefu Zhuyu Oral Liquid, and others.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jilin Aodong has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Jilin Aodong achieved revenue of $475M and an EBITDA of $259M.
Jilin Aodong expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jilin Aodong valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $475M | n/a | XXX | XXX | XXX |
| Gross Profit | $166M | $202M | XXX | XXX | XXX |
| Gross Margin | 35% | NaN% | XXX | XXX | XXX |
| EBITDA | $259M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 54% | NaN% | XXX | XXX | XXX |
| Net Profit | $245M | $245M | XXX | XXX | XXX |
| Net Margin | 52% | NaN% | XXX | XXX | XXX |
| Net Debt | $114M | $209M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Jilin Aodong's stock price is CNY 16 (or $2).
Jilin Aodong has current market cap of CNY 18.7B (or $2.6B), and EV of CNY 18.0B (or $2.5B).
See Jilin Aodong trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.6B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Jilin Aodong has market cap of $2.6B and EV of $2.5B.
Jilin Aodong's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Jilin Aodong's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jilin Aodong and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.5B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJilin Aodong's NTM/LTM revenue growth is n/a
Jilin Aodong's revenue per employee for the last fiscal year averaged $16.4M, while opex per employee averaged $6.8M for the same period.
Over next 12 months, Jilin Aodong's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jilin Aodong's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jilin Aodong and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $16.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $6.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 27% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 41% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jilin Aodong acquired XXX companies to date.
Last acquisition by Jilin Aodong was XXXXXXXX, XXXXX XXXXX XXXXXX . Jilin Aodong acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jilin Aodong founded? | Jilin Aodong was founded in 2000. |
| Where is Jilin Aodong headquartered? | Jilin Aodong is headquartered in China. |
| How many employees does Jilin Aodong have? | As of today, Jilin Aodong has 29 employees. |
| Is Jilin Aodong publicy listed? | Yes, Jilin Aodong is a public company listed on SHE. |
| What is the stock symbol of Jilin Aodong? | Jilin Aodong trades under 000623 ticker. |
| When did Jilin Aodong go public? | Jilin Aodong went public in 1996. |
| Who are competitors of Jilin Aodong? | Similar companies to Jilin Aodong include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Jilin Aodong? | Jilin Aodong's current market cap is $2.6B |
| Is Jilin Aodong profitable? | Yes, Jilin Aodong is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
